Atlas Trials

Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.

Clinical trial NCT01949467 · COMPLETED

Trial details

NCT number
NCT01949467
Sponsor
Rennes University Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hemochromatosis, Type 4Ferroportin DiseaseDysmetabolic HepatosiderosisDiagnosis
Start date
2014-02-10
Primary completion
2017-12-19
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.